CAM-H2
- Generic Name
- CAM-H2
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Phase 1
Terminated
- Conditions
- Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Precirix
- Target Recruit Count
- 13
- Registration Number
- NCT04467515
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath